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Chronic kidney disease, especially in the setting
of proteinuria, is characterized by hyperlipidemia.
In animal models, hyperlipidemia causes glomerular
foam cells and glomerulosclerosis. Treatment with
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
(statins) ameliorates kidney disease in these models. The
data of the role of hyperlipidemia in progression of human
kidney disease are less clear. Data from small studies in
glomerular disease suggest that statins decrease proteinuria.
Data mainly from cardiovascular studies suggest that statins
decrease the loss of glomerular filtration. The benefit of
statins may derive from their lipid lowering effects. More
recently, data suggest that the benefit of statins is greater
than lipid lowering alone. The pleiotropic effects of statins
may derive from inhibition of other downstream targets
(isoprenoids) of the mevalonic acid pathway that are
separate from cholesterol synthesis. Statins inhibits
isoprenylation of Ras and Rho GTPases. These effects may
lead to decreased monocyte/macrophage infiltration in the
glomerulus, decreased mesangial proliferation and decreased
accumulation of extracellular matrix and fibrosis. In addition,
inhibition of RhoA and Ras may decrease inflammation and
increase eNOS activity. These effects could lead to
improvement in the progression of kidney disease.
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Diamond1 proposed analogous pathologic mechanisms
between glomerulosclerosis and atherosclerosis, suggesting
the similarity of mesangial cells and vascular smooth muscle
cells in response to injury and emphasizing the importance of
recruitment of monocytes/macrophages that lead to further
damage. In this model, hyperlipidemia leads to acceleration
of renal damage and interventions that decrease hyper-
lipidemia or the infiltration of macrophages ameliorate
this damage. 3-Hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors or statins, which lower
low-density lipoprotein (LDL) cholesterol and have other
pleiotropic effects, have been proposed to be renoprotective,
although this remains controversial. This review discusses the
evidence of a benefit of statins on kidney injury.
LIPID ABNORMALITIES IN KIDNEY DISEASE
The dyslipidemia of chronic kidney disease is characterized
by increased triglycerides and decreased high-density lipo-
protein cholesterol.2 In the absence of proteinuria, LDL and
total cholesterol are not typically elevated. However, there are
changes in the lipoprotein composition. Decreased triglycer-
ide catabolism leads to increased remnant particles (for
example, intermediate-density lipoprotein) and triglyceride
enrichment of LDL.3 These findings are more pronounced in
diabetic nephropathy than in nondiabetic nephropathy.4
There is also an increase in small dense LDL and oxidized
LDL, both of which increase atherogenicity.5,6 In nephrotic
syndrome, there is an increase in total cholesterol and LDL.6
The level of cholesterol is directly correlated with the degree
of albuminuria and indirectly correlated with serum albumin
level.7
ASSOCIATION OF HYPERLIPIDEMIA WITH PROGRESSION OF
KIDNEY DISEASE
The finding that the high cholesterol diets induce or
exacerbate renal injury in animal models dates back to at
least the 1960s.8,9 In these models, glomerular foam cells are
seen and later stages of disease show glomerulosclerosis.
Kasiske et al.10 examined the association of a high cholesterol
diet with renal injury. Rats were fed either a high cholesterol
diet or standard chow. At 10 weeks of age, they underwent
either unilateral nephrectomy or sham surgery. At the time of
surgery, the glomerular area was 17% greater and the
fractional mesangial area was 29% greater in rats fed the
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high cholesterol diet. At 25 weeks, the rats fed a high
cholesterol diet showed an increase in glomerulosclerosis,
mesangial matrix, and cellularity (macrophage infiltration).
The effect of diet was greater than the effect of nephrectomy
and the effect of the latter on histologic damage was not
significant. However, there was a synergistic relationship of
nephrectomy and high cholesterol diet on glomerular
capillary pressure.
Most tissue culture models of lipids in kidney damage,
and later the effect of statins, have focused on the mesangial
cell. Lipids can also induce podocyte damage. Joles et al.11
found in models of unilateral nephrectomy that the early
markers of hypercholesterolemia and hypertriglyceridemia
were podocyte damage with tubulointerstitial cell activation
and injury, without mesangial cell proliferation.
Hyperlipidemia is not proposed to be a primary cause of
human kidney disease. Except for inherited diseases such as
lecithin-cholesterol acyltransferase deficiency,12 kidney dis-
ease is not a common characteristic of hyperlipidemia. More
plausible is that hyperlipidemia accelerates damage after
glomerular injury. The data for this hypothesis in human
disease are not very strong. Higher LDL cholesterol has been
found to predict the development of microalbuminuria in
type I diabetes.13 In a few small, epidemiologic studies of
individuals with glomerular disease or diabetic nephropathy,
hyperlipidemia predicted faster loss of kidney function.14,15
Samuelsson et al.,14 in a study of 73 individuals with
nondiabetic kidney disease, found that baseline LDL chole-
sterol predicted rate of glomerular filtration rate (GFR)
change, independent of baseline proteinuria. Krolewski
et al.16 evaluated predictors of fast progression (creatinine
after 3 years follow-up/baseline creatinine 41.5) in 424
individuals with type I diabetes and proteinuria. The
proportion of individuals with fast progression was 29% in
those with baseline total cholesterol o180 mg/100 ml, 24%
for 180–219 mg/100 ml, 38% for 260–299 mg/100 ml, and
48% for 4300 mg/100 ml. This finding persisted after
controlling for blood pressure; however, they did not control
for degree of proteinuria. In the RENAAL study, baseline
total cholesterol (HR (hazard ratio) 1.96 per 100 mg/100 ml
higher) and LDL cholesterol (HR 1.47 per 50 mg/100 ml
higher) were associated with a higher risk of progression to
end-stage renal disease.17 It is not clear from this report
whether they controlled for baseline proteinuria. This issue of
whether the prior studies control for proteinuria is relevant,
given the strong correlation between serum cholesterol
levels and renal albumin clearance,7 and that the degree of
albuminuria is a consistent predictor of progression of
kidney disease. Hyperlipidemia could simply be a marker
of worse underlying disease, rather than a mediator of
progression.
STATINS, PROTEINURIA, AND PROGRESSION
In animal models of kidney disease, treatment with a statin
decreases proteinuria and ameliorates pathologic
damage. There is a decrease in hypercellularity, including
macrophages, decrease in expression of inflammatory markers
(for example, interleukin-6, monocyte chemoattractant
protein-1, transforming growth factor-b, and intracellular
adhesion molecule-1), and decrease in fibrosis. This benefit is
seen in varying models of kidney disease including diabetes
(streptozotocin and obese Zucker rats), 5/6th nephrectomy,
cyclosporine, and ureteral obstruction.18–21 The benefit has
been seen with both hydrophilic (fluvastatin and pravastatin)
and lipophilic (atorvastatin, lovastatin, and simvastatin)
statins. In one study, however, the statin was needed to be
administered prior to or at the same time as the initiation of
the renal injury, which would decrease applicability to human
disease. Christensen et al.,22 in a model of immune-mediated
glomerulonephritis, administered simvastatin 6 days prior,
on the same day of, at 1 day after, and at 3 days after the
administration of nephrotoxic serum. The greatest benefit on
proteinuria was seen in animals who were pretreated,
although those treated on the same day as the sera injection
also derived a benefit. However, simvastatin was ineffective
when administered 1 or 3 days after the sera injection and the
histology was similar to untreated mice.
The evidence of the effect of statins on loss of GFR in
human studies is suggestive of a modest effect, but the
strength of evidence is not very strong. The study showing
the largest benefit was the Greek Atorvastatin and Coronary
Heart Disease Evaluation (GREACE) Study.23 The GREACE
Study randomized individuals to structured care with
titration of atorvastatin to achieve an LDL o100 mg/100 ml
compared with standard care, which could include statins
(11% on statins). In the structured treatment arm, creatinine
clearance improved by 11.6% (76±13 to 84±8 ml/min over
4 years) compared with a decline in clearance in the usual
care arm (77±12 to 74±11 ml/min). This difference was not
explained by differences in blood pressure control or use of
angiotensin-converting enzyme inhibitors (ACEIs). However,
other large studies have not seen such a large benefit and this
raises the question whether the findings were related in part
to other patient care issues. Sandhu et al.,24 in a meta-analysis
of studies investigating statins, found that simvastatin
resulted in a reduction in the rate of kidney function loss
(1.2 ml/min per year difference between medication and
placebo). It is important to differentiate the types of study
population (glomerular disease, diabetes, hypertension, and
cardiovascular disease). In subgroup analyses, only the
cardiovascular disease studies showed a statistically signifi-
cant difference. This is mainly due to the large sample size of
the cardiovascular studies that allowed a modest effect size to
be statistically significant. It is unlikely that many of the
individuals in the cardiovascular studies had intrinsic kidney
disease. The rate of decline in estimated GFR (eGFR) was
mainly 1–2 ml/min per year in contrast to the studies in
glomerular disease or diabetes where most of the studies had
an average rate of decline of 44 ml/min per year. The effect
size in the other study populations, especially in the studies
41 year in duration was greater. However, these studies have
small sample sizes and are more subject to publication bias,
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where negative studies are less likely to be published. The
dose of the statin might also be related to benefit. A recent
cardiovascular study that was published since the publication
of the meta-analysis was an analysis of the Treatment to New
Targets (TNT) Study.25 This trial randomized 10,001
individuals with coronary heart disease to 10 or 80 mg of
atorvastatin. In both groups, there was an improvement in
eGFR, but the change was greater in those who received the
higher dose (3.5±0.14 vs 5.2±0.14 ml/min per 1.73 m2). In
addition, few individuals in the higher dose arm developed
incident chronic kidney disease (eGFRo60 ml/min per
1.73 m2; 6.6 vs 9.2%).
A second recent meta-analysis analyzing the association
of statin use with reduction in albuminuria suggested
that statins did not change albuminuria in individuals
with low levels of albuminuria at baseline (o30 mg/day).26
In this study, the weighted mean difference between
statin and placebo was 2 (95% CI: 32, þ 35) for those
with baseline albuminuria o30 mg/day vs 48 (71, 25)
and 47 (67, 26) for individuals with baseline albumi-
nuria 30–299 and X300 mg/day, respectively. This is also
consistent with the analysis of the CARE Study data by
Tonelli et al.,27 who found that the improvement in slope of
decline of kidney function is greater in individuals with
proteinuria (trace or greater on dipstick). The benefit was
also greater in individuals with lower eGFR at baseline
(o40 ml/min). This study was not able to quantify whether
the improvement in slope was related to the degree of
proteinuria.
These results suggest that the renal benefit of statins may
depend on the presence of intrinsic kidney disease. They also
suggest that statins are more likely to be beneficial in
proteinuric disease (that is, glomerular disease). This could
relate to the mechanism of benefit.
EFFECT OF STATINS ON PROTEINURIA IN INDIVIDUALS
ON ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR
ANGIOTENSIN RECEPTOR BLOCKERS
Angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers (ARBs) reduce proteinuria and slow the
progression of proteinuric kidney disease, making them the
standard of care. Therefore, the clinical question is whether
statins lower proteinuria above the effect of an ACEI or ARB.
Table 1 summarizes the results from four randomized studies
that evaluated the effect of statins on proteinuria in
individuals on ACEI or ARB. The Atthobari Study in Table 1
was from PREVEND-IT, a randomized 2 2 study of
fosinopril and pravastatin in individuals with high-normal
albuminuria or microalbuminuria.30 In this study, fosinopril
decreased proteinuria, but pravastatin did not. Two of the
studies were in individuals with overt proteinuria.28,29 In
both of these studies, statin lowered proteinuria to a greater
degree than placebo. Interestingly, Lee et al. recently
published a follow-up study where they withdrew the
pravastatin in one-half of the treated individuals and
continued the pravastatin for an additional 6 months in the
other half.32 The proteinuria on those whose statin was
withdrawn returned to baseline values, while it remained
stable in those who continued on treatment.
POTENTIAL MECHANISMS OF BENEFIT OF STATINS
A number of mechanisms have been proposed to explain
the renal benefit of statins in kidney disease (Table 2).
It is not clear whether the potential renal benefits of statins
relate to lipid lowering or to other pleiotropic effects of
statins. Mesangial cells bind and uptake LDL, oxidized LDL,
intermediate-density lipoprotein via specific receptors.33 LDL
also binds to extracellular matrix when the concentration is
high where it might be subject to oxidation.34 Coritsidis et al.
Table 1 | Effect of statins on proteinuria in individuals on ACEIs or ARBs in randomized studies
Study
(reference) N
Study
duration Study population Statin ACEI/ARB
Change in
proteinuria statin
treated
Change in
proteinuria
placebo
Lee et al.28 40 6 months Hypertension;
proteinuria,
300–3000 mg/day;
nondiabetic,
creatinine,
o1.5 mg/100 ml
Pravastatin, 10 mg Losartan (average
dose 450 mg)
752±399 mg/
day
64±216 mg/day
Bianchi et al.29 56 12 months Idiopathic GN;
proteinuria
41 g/day
Atorvastatin,
10–40 mg; titrated to
LDLo120 mg/100 ml
or decline X40%
ACEI, ARB or
both—doses
not stated
45.5%
2.2±0.1 to
1.2±1.0 g/day
10%
2.1±0.1 to
1.85±0.1 g/day
Atthobari
et al.a 30
396 4 years,
2 2 design
Albuminuria
15–300 mg/day
Pravastatin
40 mg/day
Fosinopril,
20 mg/day
11.9 (95% CI:
21.1, 1.7)
23.9 (95% CI:
32.3, 14.6)
Tonolo et al.31 86 4 years Type II diabetes,
baseline GFR decline
41 ml/min per
1.73 m2 per year
Simvastatin,
40 mg/day, vs
cholestyramine,
3 g/day
Ramipril, 5 mg/
day, or lisinopril,
20 mg/day
77 (31–259)
to 40 (10–319)
(cholestyramine)
88 (34–261) to
81 (17–399)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval; GFR, glomerular filtration rate; GN, glomerulonephritis; LDL, low-
density lipoprotein.
aData presented are for those treated with fosinopril±pravastatin.
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found that LDL stimulated mesangial proliferation, while
oxidized LDL was cytotoxic in tissue culture.33,35 Rovin
et al.36 found that mesangial cells treated with LDL increase
expression of fibronectin and monocyte chemoattractant
protein-1 messenger RNA and secretion in a dose-dependent
fashion. Therefore, it is possible that beneficial effects of
statins are related to their effect on lipoprotein concentration.
It has been recognized that statins have pleiotropic effects
that may be mediated by downstream targets of the
mevalonic acid pathway that are separate from cholesterol
synthesis (Figure 1).37,38 Statins decrease the synthesis of
other isoprenoids (for example, farnesyl pyrophosphate and
geranyl geranyl pyrophosphate) which inhibits isoprenylation
of Ras and Rho GTPases.38,39 In vascular tissue, this leads
to increased endothelial nitric oxide synthase activity,
decreased oxidative stress and decreased expression of
inflammatory markers.38,40,41 The beneficial effects of statins
on mesangial proliferation, expression of transforming
growth factor-b with decrease in extracellular matrix,
monocyte chemoattractant protein-1 expression and macro-
phage infiltration in the kidney and decrease chemokine and
inflammatory marker expression may be mediated through
inhibition of Ras and RhoA.39,42,43,46–49 They also suggest
other potential targets for treatment of kidney disease.42
A more recently described mechanism of renal protection
of statins focuses on the podocyte, rather than the mesangial
cell. Podocyte damage causes proteinuria and glomerulo-
sclerosis.50 It has been proposed that the degree of podocyte
damage determines whether the glomerulus can undergo
repair compared with glomerulosclerosis (podocyte depletion
hypothesis).51 Statins ameliorate podocyte damage and
decrease podocyte apoptosis in animal models,52,53 which
could therefore decrease glomerulosclerosis. In a small
randomized study or 40 patients with chronic glomerulone-
phritis, treatment with cerivastatin decreased the number of
podocytes found in the urine, whereas there was no change in
the placebo group.54
ISSUE OF TUBULAR PROTEINURIA WITH STATINS
The Food and Drug Administration (FDA) approval of
rosuvastatin raised the controversy of statin-induced protei-
nuria. In the initial preapproval studies, the incidence of
proteinuria was higher in treated subjects, and the increase in
proteinuria was mainly seen in those taking 80 mg (not an
FDA-approved dose), but there was a trend for the 40-mg
dose as well.55 The proposed mechanism of the proteinuria is
tubular inhibition of protein uptake.55 In a tissue culture
model using human kidney tubular cells, simvastatin,
pravastatin, and rosuvastatin decreased receptor-mediated
protein endocytosis of albumin in proximal tubular cells in a
dose-dependent fashion.56 There was no effect on cell
viability. Whether there are differences between statins in
in vivo models is not clear, as most prior studies of statins
in nonkidney disease populations have not systematically
evaluated for proteinuria. If the medication needs to act from
the luminal surface to inhibit the uptake of proteinuria, it is
theoretically possible that rosuvastatin would have a greater
effect as a larger proportion of the medication is filtered and
excreted unchanged. However, it is important to recognize
that the increase in proteinuria with rosuvastatin has not led
to a greater risk of acute injury or progression of kidney
disease.57,58 The National Lipid Association Statin Safety
Task Force recent conclusions were that in the absence
of rhabdomyolysis, statins do not cause acute renal failure or
insufficiency.59,60 The ongoing PLANET studies will compare
10 mg rosuvastatin 80 mg with atorvastatin on change in
proteinuria in individuals with diabetic (PLANET I) and
nondiabetic (PLANET II) over 1 year (Clinicaltrials.gov;
NCT 00296400, NCT 00296374).
CONCLUSION
Statins are effective cholesterol-lowering medications that
decrease cardiovascular disease. They may also have beneficial
effects on ameliorating the damage from kidney disease. This
benefit may be secondary to the pleiotropic effects of statins
Table 2 | Potential mechanism of statin benefit in kidney
disease
Inhibit mesangial proliferation
Inhibit induction of TGF-b and increase in extracellular matrix
Inhibition of induction of MCP-1
Decrease in macrophage infiltration
Decrease in inflammation and oxidative stress
Ameliorate podocyte damage
Hemodynamic effects on endothelial function and vasodilation
Ameliorate renal vascular disease
MCP-1, monocyte chemoattractant protein-1; TGF-b, transforming growth factor-b.
HMG-CoA
Statins
Mevalonic acid
Isopentyl-5-pyrophosphate
Geranyl pyrophosphate
Farnesyl pyrophosphate
Geranyl pyrophosphate Ras
Inflammation  
↑ PAI-1 ↓ eNOS
and ↑ endothelin
Squalene
Cholesterol RhoA Rac1 Cell proliferation
Oxidative stressCell proliferation ↑ ECM
Figure 1 | Mevalonic acid pathway and implications for
kidney disease. ECM¼ extracellular matrix. Data from Liao,37,38
Kim et al.,39 Rikitake and Liao,40 Vecchione et al.,41 Gojo et al.,42
Toblli et al.,43 Xu et al.,44 and McTaggart.45
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and not solely to lipid lowering. The current data on renal
benefit are not clear and, at this time, statins should be
prescribed for cardiovascular disease. The future results of the
Study on Heart and Renal Protection (SHARP) should help
define the role of statins on progression of kidney disease, as
well as cardiovascular disease in individuals with chronic
kidney disease.
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